This article summarizes presentations from the Second International Symposium on Myelodysplastic Syndromes in Childhood, May 11 to 14, 2000, in Funen, Denmark. Topics included epidemiology, pathology, pathophysiology, cytogenetics, congenital neutropenia, transplantation, and classification. Dr. Henrik Hasle was the Meeting Chair and Dr. Gitte Kerndrup was the Co-Chair.
Over 300 representatives, including 20 ministers of health, attended the 52nd session of the World Health Organisation (WHO) Regional Committee for Europe, which was held from 16 to 19 September in Copenhagen, Denmark. On this occasion the European Health Report 2002 was released. This report confirms the strong links between socioeconomic development, health and equity in the WHO European Region which covers 51 WHO Member States with some 870 million people. While overall levels of health in the Region are among the highest in the world, the report describes widening gaps between and within countries (www.euro.who.int/europeanhealthreport).
Atopic dermatitis is a common condition, with a lifetime prevalence of approximately 10% to 20% among the Canadian population. A clear, practical, Canadian guideline for the management of these patients has been lacking.
To provide primary-care physicians, pediatricians and dermatologists with the first practical and comprehensive set of Canadian recommendations for the management of atopic dermatitis.
A group of Canadian dermatologists convened to review the current issues of diagnosis, treatment and international guidelines and adapt them to the Canadian context. The reviewers used the latest clinical trial data on atopic dermatitis, complemented by clinical experience, to develop the consensus recommendations found in this review.
In the present report, following a brief review of the epidemiology of and clinical diagnosis criteria for atopic dermatitis, the recommendations for treatment and management are detailed. These recommendations, which are intended to provide clinicians with a useful and valuable tool to help manage their patients with atopic dermatitis, are divided into the following sections: epidemiology, diagnosis, general measures/skin care, acute management of atopic dermatitis, long-term management/disease control, adjunct therapies, and considerations for switching between antiinflammatory therapies/handling treatment failure. General measures discussed include hydration with bathing and the use of moisturizers. Management strategies discussed include topical corticosteroids, topical calcineurin inhibitors, antihistamines and anti-infectives. A management algorithm is also presented.
Several government and nongovernment organizations held a consensus conference on the management of acute and chronic viral hepatitis to update previous management recommendations. The conference became necessary because of the introduction of new forms of therapy for both hepatitis B and hepatitis C. The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon. The treatment of hepatitis B in several special situations was also discussed. There were also recommendations on the investigation and treatment of chronic hepatitis C and hepatitis C-HIV coinfection. In addition, the document makes some recommendations about the provision of services by provincial governments to facilitate the delivery of care to patients with hepatitis virus infection. The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care.